Bio-Rad Laboratories

Oncocyte Reports Full Year 2023 Financial Results

Retrieved on: 
Friday, April 12, 2024
Kidney, IP, Bio-Rad Laboratories, Research, Security (finance), Partnership, OCX, Eastern Time Zone, Marketing, Telephone, Cryptocurrency

IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023.

Key Points: 
  • IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023.
  • Q1 2024 cash burn, respectively
    “In 2023, we made significant progress on cost controls and in the development of our transplant monitoring IP,” said Josh Riggs, CEO of Oncocyte.
  • For Oncocyte’s complete financial results for the year ended December 31, 2023, see the Company’s annual Form 10-K to be filed with the Securities and Exchange Commission on April 15, 2024.
  • Oncocyte will host a conference call to discuss fourth quarter and full year 2023 financial results prior to market open on Friday, April 12, 2024 at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time.

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

Retrieved on: 
Thursday, April 11, 2024
FDA, Bio-Rad Laboratories, Security (finance), Partnership, Research, DdPCR, PCR, Transplant, OCX, IVD, Pharmaceutical industry

IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the commercialization of its research use only GraftAssure™ assay, powered by Droplet Digital™ PCR (ddPCR™)*. The new product is expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU and more broadly in the second half of the year.

Key Points: 
  • The new product is expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU and more broadly in the second half of the year.
  • As part of the agreement, Bio-Rad and Oncocyte will co-market the assay inside the US and Germany, with Oncocyte acting as commercial lead.
  • Outside these countries Bio-Rad has been granted exclusive global distribution and commercial rights.
  • Additionally, Bio-Rad has been granted an option for IVD commercial rights at FDA clearance, subject to meeting specific objectives.

Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Diabetes, Health, Other Health, Pharmaceutical, Stem Cells, Research, Medical Devices, Infectious Diseases, General Health, Science, COVID-19, Clinical Trials, Medical Supplies, Bio-Rad Laboratories, Conference

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).

Key Points: 
  • Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).

Sphere Fluidics Appoints Dale Levitzke as Chief Executive Officer

Retrieved on: 
Tuesday, April 30, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Health Technology, Lead, Single-cell analysis, Bio-Rad Laboratories, Microfluidics, Marketing, NanoString Technologies, Molecular biology, Genetics, Retirement, IPO, Sphere, Senior, Bachelor of Science, Sphere Fluidics, Acquisition, Synthetic biology, Illumina, Inc., La Trobe University

In his role as CEO, Dale will shape Sphere Fluidics’ future commercial business and progress the Company’s continued global expansion strategy to reach new customers and create value for shareholders.

Key Points: 
  • In his role as CEO, Dale will shape Sphere Fluidics’ future commercial business and progress the Company’s continued global expansion strategy to reach new customers and create value for shareholders.
  • Throughout his career, Dale has focused on supporting early-stage and VC-backed pioneering tools companies and steering them towards global market success.
  • Dr. Frank F. Craig co-founded Sphere Fluidics, alongside Professor Chris Abell and Professor Wilhelm Huck, before becoming CEO in 2010.
  • Dale Levitzke, incoming CEO, Sphere Fluidics, added: “Sphere Fluidics’ picodroplet technology and microfluidics platforms are transforming single cell analysis and isolation capabilities, bringing new possibilities to biopharmaceutical research and development.

Agilent Names Simon May to Lead Diagnostics and Genomics Group

Retrieved on: 
Monday, April 29, 2024
Science, Software, Other Science, Biotechnology, Health, Health Technology, Technology, Genetics, Bio-Rad Laboratories, Agilent Technologies, Simon May, DGG, Thermo Fisher Scientific, Management

Agilent Technologies, Inc. (NYSE: A) today announced Simon May has been named president of the company’s Diagnostics and Genomics Group (DGG).

Key Points: 
  • Agilent Technologies, Inc. (NYSE: A) today announced Simon May has been named president of the company’s Diagnostics and Genomics Group (DGG).
  • May, previously executive vice president and president of the Life Science Group at Bio-Rad Laboratories, will join Agilent on May 6.
  • “We are excited to welcome Simon May to the Agilent team,” said Padraig McDonnell, COO and CEO-elect.
  • Before joining Bio-Rad in 2014, May held positions at Thermo Fisher Scientific for 10 years as well as MWG Biotech.

Bio-Rad Announces Life Science Group Management Changes

Retrieved on: 
Friday, April 26, 2024
Science, Other Science, Biotechnology, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Executive, Genomics, Mechanical engineering, Rose–Hulman Institute of Technology, Bio-Rad Laboratories, Hospital, Research, Mechanical, Senior, Pepperdine University, Data management, Beckman Coulter, MBA, Strategic planning, Management

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice President and President of the Life Science Group, effective May 1, 2024.

Key Points: 
  • Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice President and President of the Life Science Group, effective May 1, 2024.
  • He succeeds Dr. Simon May, who has announced his decision to leave the company to pursue another professional opportunity.
  • For the past two years, James Barry has been responsible for Bio-Rad’s global manufacturing operations including quality, planning, and continuous improvement initiatives across the organization.
  • "On behalf of the senior management team, I would also like to thank Simon May for his valuable contributions to Bio-Rad and to the Life Science Group,” Mr. Schwartz continued.

Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Retrieved on: 
Thursday, April 18, 2024
Science, Other Science, Biotechnology, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, Bio-Rad Laboratories, Research, Webcast

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market.

Key Points: 
  • Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market.
  • Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
  • To participate, dial 800-274-8461 within the U.S. or (+1) 203-518-9814 outside the U.S., access code: BIORAD.
  • A live webcast of the conference call will also be available in the "Investor Relations" section of the company’s website under "Events & Presentations" at investors.bio-rad.com .

United States In-Vitro Diagnostics Market Insights 2024-2029: Increasing Adoption Of Automation in Laboratories and Growing Importance of IVD In Healthcare Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, April 15, 2024
Genetics, Health, Oncology, Other Health, USD, Cancer, Pandemic, Automation, Risk, Thermo Fisher Scientific, Bio-Rad Laboratories, Hospital, Hematology, Siemens Healthineers, Diabetes, Calibration, Genetic testing, Infection, Documentation, 2005 in television, Diagnosis, COVID-19, IVD, Growth, Liquid biopsy, Medical device

The leading market players in the US IVD market are F Hoffmann-La Roche, Abbott, Thermo Fisher Scientific, Diasorin, Biomerieux, Danaher, Bio-Rad, and Siemens Healthineers, competing with rapidly emerging market players.

Key Points: 
  • The leading market players in the US IVD market are F Hoffmann-La Roche, Abbott, Thermo Fisher Scientific, Diasorin, Biomerieux, Danaher, Bio-Rad, and Siemens Healthineers, competing with rapidly emerging market players.
  • Vendors in the market are increasing their market share through inorganic growth strategies.
  • The reagents and consumables product segment occupies a major market share of over 67% in the U.S. in-vitro diagnostics (IVDs) market.
  • What is the growth rate of the U.S. in-vitro diagnostics (IVDs) market?

Global Research Antibodies & Reagents Market Outlook & Forecasts, 2023 and 2024-2029: Growing Demand for Precision Medicine, Rising Focus on Biomarker Discovery, & Rise in Proteomics and Genomics - ResearchAndMarkets.com

Retrieved on: 
Friday, April 12, 2024
Health, Stem Cells, Genetics, Research, Science, Biotechnology, USD, Immunoprecipitation, Antibody, Cancer, Genomics, Protein, Cell biology, ELISA, Heart, Personalized medicine, Proteomics, Immunohistochemistry, Biomedical Research, Biomarker, Growth, University, Disease, ChromeOS, Bio-Rad Laboratories, Therapy, Northern blot, Patient, Chemistry, Medicine, Diagnosis, Antigen, Gene expression, Genome, Elisa's, Drug development, Biology, Molecular biology, Drug discovery, Thermo Fisher Scientific, Gene, Flow cytometry, Fine chemical

North America holds the most prominent share of the global research antibodies & reagents market, accounting for over 39% in 2023.

Key Points: 
  • North America holds the most prominent share of the global research antibodies & reagents market, accounting for over 39% in 2023.
  • This paradigm shift presents a substantial opportunity for the research antibodies & reagents market, an essential component of precision medicine research.
  • The reagents product type accounted for the most significant global research antibodies & reagents market share in 2023.
  • The academics & research institutes and research labs end-user segment dominated the global research antibodies & reagents market share in 2023.

Bio-Rad’s Chief Operating Officer Andrew Last to Retire

Retrieved on: 
Wednesday, April 10, 2024
Other Health, Research, General Health, Pharmaceutical, Infectious Diseases, Clinical Trials, Science, Biotechnology, Medical Supplies, Other Science, Health, Diabetes, Bio-Rad Laboratories, Management

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024.

Key Points: 
  • Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024.
  • Dr. Last will remain part of Bio-Rad’s executive leadership team to ensure a smooth transition while the company conducts a search for his successor.
  • Dr. Last joined Bio-Rad in April of 2019 with over 30 years of experience in global operations management spanning the life sciences.
  • I am confident that these accomplishments have positioned Bio-Rad well for the next phase of its continued journey of transformation and growth.”